The burgeoning landscape of treatment for excess body fat and type 2 metabolic disorder is currently witnessing considerable interest surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 receptor agonists, significant differences in their pharmacological profiles and clinical investigation results are emerging… Read More

Showing promise in the field of excess body fat therapy, retatrutide represents a unique approach. Beyond many existing medications, retatrutide works as a twin agonist, concurrently affecting both GLP-like peptide-1 (GLP-1) and glucose-dependent insulinotropic substance (GIP) binding sites. This dual stimulation promotes multiple advantageous effe… Read More